We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Scientists Decode Sparse Genome of Microbe Linked to Autoimmunity

By LabMedica International staff writers
Posted on 27 Sep 2011
Scientists have deciphered the genome of a bacterium implicated as a major player in regulating the immune system of mice. More...
The genomic analysis provides the first insights into its strangely sparse genetic blueprint and offers clues about how it may activate a powerful immune response that protects mice from infection but also triggers harmful inflammation.

The researchers, led by Dan Littman, a professor of molecular immunology at New York University (NYU) School of Medicine (New York, NY, USA), and Ivaylo Ivanov, PhD, of Columbia University Medical Center (New York, NY, USA) published their findings in the September 15, 2011, issue of the journal Cell Host and Microbe. The study suggests that the gut-dwelling microorganism, called segmented filamentous bacteria (SFB), is genetically different from all 1,200 bacterial genomes examined so far, reflecting its comparatively unique role in the gut.

Although SFB was first identified more than 40 years ago, it was not until 2009 that Dr. Littman and an international team of collaborators discovered that it can recruit specialized T cells, called Th17 cells, in the small intestine of mice. These potent immune cells, they subsequently found, protected the mice from disease-causing Citrobacter rodentium bacteria, but also made them more prone to inflammation and autoimmune arthritis. Those early findings suggested other intestinal bacteria might also regulate immune function.

“What has become clear in the last couple of years is that individual bacteria can specifically influence particular branches of the immune system,” noted Dr. Littman. In the new study, his team decoded SFB’s 1.57 million letters of DNA, nearly 2,000 times smaller than our own genome and about one-third the size of its closest relative.
The microbe’s scant genome lacks many genes needed for its own survival, such as ones for making amino acids and other essential nutrients. As a result, it is dependent on other gut-dwelling bacteria or its host for food, according to the study. The study of its 1,500 genes, however, suggests it is well adapted to the small intestine, where it clings to the thin lining and may help prevent other microbes from breaching the barrier.

Although the research did not uncover any definitive signs of the SFB living within humans, Dr. Littman suspects the resourceful bacteria have adapted to specific human populations. Even if it is not found in the intestinal tract, scientists could apply what they have learned to obtain insights into the function of similarly acting microorganisms within the body. “Maybe in humans, there is another bacterium that is different from SFB but behaves functionally in the same way,” said Dr. Ivanov, who conducted the latest analysis as a postdoctoral researcher in Dr. Littman’s lab.

Recently, Japanese researchers found intestinal bacteria in humans that can boost development of regulatory immune cells in mice, thereby keeping the inflammatory activity of Th17 cells in check. Dr. Littman and his NYU collaborators may have also discovered a microbe in the intestinal tract of rheumatoid arthritis patients that alters immune function. These emerging results underscore the need to understand how the microbes living in humans may impact health.

“This research brings us the potential genetic mechanisms that trigger differentiation of Th17 cells which we have long believed to have a strong role in the development of autoimmune diseases, including rheumatoid arthritis [RA], psoriatic arthritis [PsA], and Crohn’s disease,” said Steven Abramson, MD, professor, departments of medicine and pathology and director of the rheumatology division at NYU Langone Medical Center. “With more than 50 million Americans suffering from at least one autoimmune disease, this research gives scientists and clinicians a greater ability to apply knowledge gained in the laboratory to actual clinical cases, moving it from ‘bench-to-beside’ to give patients a tremendous advantage and physicians the ability to fine-tune medications and protocols based on patient response.”

Related Links:
New York University School of Medicine
Columbia University Medical Center





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.